mucin 1-specific allogeneic CAR T-cell therapy (Cellectis)

N/A

Report date: 2025/01/26 15:46:56

Base Information

Drug Namemucin 1-specific allogeneic CAR T-cell therapy (Cellectis)

Drug Alias Nameallogeneic anti-MUC1 CAR T-cell therapy (Cellectis)UCARTMUC1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionMucin-1 modulators

TargetsMucin-1

Therapy Area/IndicationsSolid tumoursTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCellectis Sa

China Registration ClassN/A

Develop Information

Active CompaniesCellectis Sa

Inactive CompaniesN/A

Active IndicationsSolid tumoursTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A